ArthroCare Receives FDA Clearance for Parallax Contour Vertebral (ARTC)

ArthroCare Corp. (NASDAQ: ARTC) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Parallax® Contour® Vertebral Augmentation Device specifically for void creation in a vertebral body followed by injection of bone cement. Vertebral body void creation followed by bone cement augmentation is commonly used to treat painful vertebral compression fractures. The newly cleared Indication Statement provides that the Contour device is indicated for use during kyphoplasty or vertebral augmentation procedures to create a void in the vertebral body and fill the void with Parallax Acrylic resin. Pathological vertebral body compression fractures may result from osteoporosis, benign or malignant lesions such as metastatic cancers and myeloma. Don't miss these trading ideas!